Discovery and clinical evaluation of 1-{N-[2-(amidinoaminooxy)ethyl]amino}carbonylmethyl-6-methyl-3-[2,2-difluoro-2-phenylethylamino]pyrazinone (RWJ-671818), a thrombin inhibitor with an oxyguanidine P1 motif

Journal of Medicinal Chemistry
Tianbao LuMark R Player

Abstract

We have identified RWJ-671818 (8) as a novel, low molecular weight, orally active inhibitor of human alpha-thrombin (K(i) = 1.3 nM) that is potentially useful for the acute and chronic treatment of venous and arterial thrombosis. In a rat deep venous thrombosis model used to assess antithrombotic efficacy, oral administration of 8 at 30 and 50 mg/kg reduced thrombus weight by 87 and 94%, respectively. In an anesthetized rat antithrombotic model, where electrical stimulation of the carotid artery created a thrombus, 8 prolonged occlusion time 2- and 3-fold at 0.1 and 1.0 mg/kg, i.v., respectively, and more than doubled activated clotting time and activated partial thromboplastin time at the higher dose. This compound had excellent oral bioavailability of 100% in dogs with an estimated half-life of approximately 3 h. On the basis of its noteworthy preclinical data, 8 was advanced into human clinical trials and successfully progressed through phase 1 studies.

References

May 25, 1977·Journal of Molecular Biology·F C BernsteinM Tasumi
Oct 15, 1992·Thrombosis Research·W A SchumacherS K Durham
Apr 29, 1994·Journal of Medicinal Chemistry·F J BrownR C Green
Sep 23, 1997·Toxicology and Applied Pharmacology·J D ObournJ C Cook
Mar 9, 2000·Thrombosis Research·E C GiardinoP Andrade-Gordon
Jun 8, 2001·Circulation Research·C PattersonM S Runge
Apr 6, 2002·Bioorganic & Medicinal Chemistry Letters·John E ReinerJ Edward Semple
Dec 21, 2002·European Journal of Clinical Investigation·J WalkowiakK-H Herzig
Jan 23, 2003·The Journal of Pharmacology and Experimental Therapeutics·J LorrainS E O'Connor
Mar 6, 2003·Bioorganic & Medicinal Chemistry Letters·Philip E J SandersonYouwei Yan
Apr 2, 2003·Bioorganic & Medicinal Chemistry Letters·Bruce TomczukRoger Bone
Apr 23, 2004·Expert Opinion on Investigational Drugs·Mark A Crowther, Jeffrey I Weitz
May 28, 2004·Journal of Medicinal Chemistry·Mary Beth YoungPhilippe G Nantermet
Jan 5, 2005·Journal of the American College of Cardiology·Jonathan L Halperin
Nov 1, 2005·Bioorganic & Medicinal Chemistry Letters·Richard C A IsaacsBobby J Lucas
Jan 23, 1987·Science·A T BrüngerM Karplus
Feb 21, 2009·Cardiovascular Research·Julian Ilcheff BorissoffHugo ten Cate
Apr 18, 2009·Anesthesia and Analgesia·Kenichi A TanakaJerrold H Levy
Apr 25, 2009·Nature Reviews. Drug Discovery·Irena Melnikova

❮ Previous
Next ❯

Citations

Jun 18, 2015·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Li-Wei HeNian-Guang Li
Aug 16, 2014·Tetrahedron Letters·Qingjie ZhaoJonathan L Vennerstrom
Sep 20, 2012·Natural Product Reports·Roberto G S BerlinckMario F C Santos
Mar 19, 2011·Journal of Medicinal Chemistry·Nicholas A Meanwell
Apr 5, 2013·The Journal of Organic Chemistry·Jhonny AzuajeEddy Sotelo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.